Recent posts
It started out business as usual at the Personalized Medicine Coalition’s East Coast reception at The Broad Institute last week. People were touting the big steps that have been taken to... Read more »
Back when I was starting out in some lowly jobs at the Longwood Medical area, I was constantly reminded of the greatness of certain of the people around me. But one... Read more »
It wasn’t apparent, but when I spoke to him just before Christmas, Stephen A. Hill might have been mentally packing his suitcase. In any event, Woburn, MA-based biotech ArQule (NASDAQ:ARQL... Read more »
Massachusetts became even more firmly established as the preeminent center of commercial RNAi activity last year when two more such companies were founded here—Worcester-based RXi (a spinout of CytRx) and Boston-based... Read more »
With its aim of growing replacements for injured or ailing body parts, tissue engineering is a field that at first seemed spectacularly promising. (Anyone remember the mouse with a human ear... Read more »
Idera Pharmaceuticals (NASDAQ:IDRA) has netted its third major deal in about as many years. This one, potentially worth upwards of $400 million to the Cambridge, MA-based biotech, is a... Read more »
2007 has been an outstanding year for stem cells—those much-ballyhooed cells with the ability to develop into numerous tissues in the body and ultimately, researchers hope, repair the damage in ailments... Read more »
At a conference yesterday, Millennium Pharmaceuticals (NASDAQ: MLNM) presented positive clinical data that could boost the Cambridge, MA-based company’s chances of gaining a broadened approval for cancer-drug Velcade, Millennium’s only... Read more »
Waltham, MA-based Inverness Medical Innovations (AMEX: IMA) has agreed to pay $170 million in stock for BBI Holdings, a UK company that specializes in lateral-flow tests, such as those used... Read more »
As I wrote in Wednesday’s post on Aveo’s deal with Eli Lilly, the biomarker business is finally having a growth spurt, at least in oncology. Another intriguing company trying to... Read more »
Until recently it seemed like the only thing big pharmaceutical companies wanted from the little guys was their drugs—as many of them as the pharmas could get their hands on. Things... Read more »
What if within the next decade or so the U.S. healthcare system was completely transformed? Hospitals like Boston’s Beth Israel were all replaced by retail clinics and medical centers specializing in... Read more »
One of the most controversial drugs ever made could disappear if a new marketing plan can’t save it.
Widely known as the “race-based” medicine, BiDil (isosorbide dinitrate and hydralazine hydrochloride) was... Read more »
Cambridge, MA-based Ariad Pharmaceuticals (NASDAQ: ARIA) has made three key new appointments in anticipation of the launch of its first product and the growth of its pipeline. Matthew E. Ros... Read more »
Waltham, MA-based Inverness Medical Innovations (AMEX: IMA) netted a tidy $806.4 million by selling 13,634,302 shares at $61.49 in a public offering that closed yesterday. All told the deal—which... Read more »
Cambridge, MA-based Vertex Pharmaceuticals (Nasdaq: VRTX) yesterday announced a potentially serious setback in its program to develop novel cancer drugs aimed at a family of enzymes called the Aurora kinases.... Read more »
It’s not the Massachusetts deal everyone was waiting for—as all eyes have been on Biogen Idec and, more recently, Genzyme. But Pfizer (NYSE: PFE) finally pounced again today, announcing... Read more »
With a fast-tracked drug in one hand and too little money in the other, Cambridge, MA-based Molecular Insight Pharmaceuticals (NASDAQ: MIPI) recently settled on a bond financing to get one... Read more »
Boston-based RNAi therapeutics startup Dicerna is finally officially out of the gates with a finalized $13M Series A financing led by Oxford Bioscience Partners and Skyline Ventures. (I profiled Dicerna... Read more »
It’s been buy, buy, buy, for the last couple of years. Then last Thursday, Waltham, MA-based Inverness Medical Innovations (AMEX: IMA) announced it plans to sell 7 million new shares—the... Read more »
